Meet the leadership team who create an environment enabling over 6000 of the world’s top leaders and subject matter experts to benchmark and collaborate on over 90 global missions.
Cell & Gene Therapy
Cell and gene therapy is an exciting, fast moving area of…
Bringing the industry’s brightest minds together…
Drug Substance is the place where the twin aims of delivering medicines to today’s patients…
We have a fantastic collaborative portfolio covering all the major areas…
I enjoy working with technology leaders to provide them with the opportunity to consider and plan a path to their future state…
Mat joined BioPhorum from Apex Medical UK in April 2022 as Group Phorum Director…
I am proud to have built up BioPhorum Supply Partner into one of…..
Nicola has been with BioPhorum since 2019. Initially focusing on raw materials…..
Chief Executive Officer
Tim joined BioPhorum as Chief Executive Officer, bringing over 20 years of leadership experience in healthcare, technology and the pharmaceutical industry.
Chief Operating Officer
Alison is an experienced technical leader, having spent most of her career working in the pharmaceutical industry. She is a Chartered Chemical Engineer and has over 15 years of experience in a wide range of operational and technical leadership roles and consultancy.
Chief Financial Officer
Tim is an experienced CFO operating within the Private Equity and VC-backed business environment, having worked within software and technology-led businesses for the last 20 years, in both the SME and Nasdaq environments.
Darren is an accomplished practitioner in operations and change management, having acquired his capability through a combination of consulting and leadership positions spanning more than 25 years.
Steve has over 25 years’ experience, gained across the automotive, aerospace, pharmaceutical and technology sectors.
Head of Business Development
Katriina joined BioPhorum at the beginning of 2022 as a Business Development Director before taking the position of Head of Business Development from April 2022.